Chemotherapy-Induced Peripheral Neuropathy (CIPN): Non-Opioid Treatment Options
Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage caused by cancer-treatment drugs, most often felt as burning, tingling, or numbness in the hands and feet. The NS100 by NeuroDynamics Global is an FDA-cleared 20-day temporary neuromodulation therapy used by physicians to help reduce chronic neuropathic pain without a permanent implant and without opioids.
What is chemotherapy-induced peripheral neuropathy?
Chemotherapy-induced peripheral neuropathy (CIPN) is nerve damage caused by certain cancer-treatment drugs — most commonly platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide. It typically appears during or after chemotherapy and can persist for months or years after treatment ends.
Symptoms usually start in the hands and feet and include burning pain, tingling, numbness, sharp electric-shock sensations, sensitivity to cold, and difficulty with fine motor tasks like buttoning a shirt or holding a cup. Severe CIPN can disrupt sleep, balance, and quality of life.
CIPN affects an estimated 30–40% of patients receiving neurotoxic chemotherapy. For many, it is the symptom that most limits daily function during cancer survivorship.
Key facts
- 20-day temporary therapy — no permanent implant
- FDA-cleared Class II medical device for chronic pain
- Non-opioid, non-pharmacologic — no systemic drug side effects
- Placed in a minimally invasive in-office procedure
- Removed in a simple in-office visit on day 20
- Used by physicians as an option when first-line CIPN medications have failed
Why it matters
20-day protocol
A defined, time-limited course of therapy — worn continuously for 20 days, then removed.
FDA-cleared
Class II peripheral nerve stimulation system cleared for chronic pain.
Peripheral nerve target
Delivers gentle electrical stimulation directly to peripheral nerves to help modulate pain signals.
Provider supervised
Placed and removed by a trained physician in a minimally invasive in-office procedure.
How NS100 by NeuroDynamics Global is used for chronic neuropathic pain
NS100 is a peripheral nerve stimulation (PNS) system that delivers programmable electrical pulses to peripheral nerves involved in neuropathic pain. It is FDA-cleared for chronic pain associated with painful diabetic neuropathy; physicians may evaluate it as part of a chronic neuropathic pain treatment plan based on clinical judgment.
Because NS100 is temporary, there is no implanted pulse generator, no permanent hardware to maintain, no battery to replace, and no surgery to remove a permanent device. At the end of the 20-day protocol the leads are removed in a simple in-office visit.
Eligibility, candidacy, and expected outcomes are determined by your treating provider. Individual results vary.
How NS100 differs from typical CIPN treatments
First-line CIPN pain treatments often include duloxetine, gabapentin, pregabalin, tricyclic antidepressants, topical agents, and opioids. These can carry systemic side effects and may not provide adequate relief for every patient.
NS100 is non-pharmacologic, non-opioid, and avoids systemic drug exposure. Compared with permanent implants such as spinal cord stimulators, it is removed after 20 days — there is no permanent device left in the body.
Frequently asked questions
Ready to learn if NS100 is right for you?
Connect with our team. We'll help you understand candidacy, coverage, and next steps.